CL2018002962A1 - Treatment of progressive ossifying fibrodysplasia (divisional of application No. 603-2017. - Google Patents

Treatment of progressive ossifying fibrodysplasia (divisional of application No. 603-2017.

Info

Publication number
CL2018002962A1
CL2018002962A1 CL2018002962A CL2018002962A CL2018002962A1 CL 2018002962 A1 CL2018002962 A1 CL 2018002962A1 CL 2018002962 A CL2018002962 A CL 2018002962A CL 2018002962 A CL2018002962 A CL 2018002962A CL 2018002962 A1 CL2018002962 A1 CL 2018002962A1
Authority
CL
Chile
Prior art keywords
acvr2a
acvr2b
divisional
treatment
application
Prior art date
Application number
CL2018002962A
Other languages
Spanish (es)
Inventor
Vincent J Idone
Sarah J Hatsell
Aris N Economides
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2018002962A1 publication Critical patent/CL2018002962A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE PROPORCIONAN MÉTODOS PARA TRATAR LA FIBRODISPLASIA OSIFICANTE PROGRESIVA (FOP). TALES MÉTODOS IMPLICAN LA ADMINISTRACIÓN A UN SUJETO QUE TIENE : FOP UN RÉGIMEN EFICAZ DE ANTAGONISTA DEL RECEPTOR DE LA ACTIVINA TIPO 2A (ACVR2A) Y/O UN RECEPTOR DE LA ACTIVINA TIPO 2B (ACVR2B) O UN ANTAGONISTA DEL RECEPTOR DE LA ACTIVINA TIPO 1 (ACVR 1). LOS ANTAGONISTAS INCLUYEN LAS PROTEÍNAS DE FUSIÓN DE  UNO O MÁS DOMINIOS EXTRACELULARES (ECD) DE ACVR2A, ACVR2B Y/O ACVR1 Y EL DOMINIO FE DE UNA CADENA PESADA DE ININUNOGLOBULINA, Y ANTICUERPOS CONTRA ACVR2A, ACVR2B,  ACVR1 O ACTIVINA A.METHODS ARE PROVIDED TO TREAT PROGRESSIVE OSIFYING FIBRODISPLASIA (FOP). SUCH METHODS IMPLY THE ADMINISTRATION TO A SUBJECT THAT HAS: FOP AN EFFECTIVE ANTAGONIST RECEIVER REGIME OF TYPE 2A ACTIVINE (ACVR2A) AND / OR A TYPE 2B ACTIVINE RECEIVER (ACVR2B) OR AN ACTIVITY RECEPTOR ANTIGONIST (ACVR 1). THE ANTAGONISTS INCLUDE THE FUSION PROTEINS OF ONE OR MORE EXTRACELLULAR DOMAINS (ECD) OF ACVR2A, ACVR2B AND / OR ACVR1 AND THE FAITH DOMAIN OF A HEAVY CHAIN OF ININUNOGLOBULIN, AND ANTIBODIES AGAINST ACVR2B, ACVRBAA, ACVR2A, ACVR2A, ACVR2A, ACVR2A, ACVR2A, ACVR2A, ACVR2A, ACVR2A, ACVR2A, ACVR2A, ACV

CL2018002962A 2014-09-12 2018-10-17 Treatment of progressive ossifying fibrodysplasia (divisional of application No. 603-2017. CL2018002962A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049869P 2014-09-12 2014-09-12
US201562141775P 2015-04-01 2015-04-01

Publications (1)

Publication Number Publication Date
CL2018002962A1 true CL2018002962A1 (en) 2018-12-28

Family

ID=54207748

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017000603A CL2017000603A1 (en) 2014-09-12 2017-03-10 Treatment of progressive ossifying fibrodysplasia
CL2018002962A CL2018002962A1 (en) 2014-09-12 2018-10-17 Treatment of progressive ossifying fibrodysplasia (divisional of application No. 603-2017.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017000603A CL2017000603A1 (en) 2014-09-12 2017-03-10 Treatment of progressive ossifying fibrodysplasia

Country Status (28)

Country Link
US (3) US20160075772A1 (en)
EP (2) EP3191512B1 (en)
JP (1) JP6560341B2 (en)
KR (1) KR102564079B1 (en)
CN (1) CN107106648B (en)
AU (1) AU2015315829B2 (en)
CA (1) CA2960950C (en)
CL (2) CL2017000603A1 (en)
CY (1) CY1122188T1 (en)
DK (1) DK3191512T3 (en)
ES (1) ES2739605T3 (en)
HR (1) HRP20191929T1 (en)
HU (1) HUE046558T2 (en)
IL (1) IL251063B (en)
LT (1) LT3191512T (en)
MA (1) MA40621B1 (en)
ME (1) ME03541B (en)
MX (1) MX2017003175A (en)
MY (1) MY179654A (en)
NZ (1) NZ730773A (en)
PL (1) PL3191512T3 (en)
PT (1) PT3191512T (en)
RS (1) RS59412B1 (en)
SG (2) SG11201701913SA (en)
SI (1) SI3191512T1 (en)
TW (1) TWI688402B (en)
WO (1) WO2016039796A2 (en)
ZA (1) ZA201702112B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2780368T3 (en) 2011-11-14 2018-06-29 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
TW201920262A (en) 2013-07-30 2019-06-01 美商再生元醫藥公司 Anti-activin A antibodies and uses thereof
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
US10934349B2 (en) 2015-04-15 2021-03-02 Regeneron Pharmaceuticals, Inc. Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that is an anti-GDF8 antibody
WO2016171948A1 (en) 2015-04-22 2016-10-27 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
EP3415527A1 (en) 2017-06-14 2018-12-19 Technische Universität Dresden Use of the extracellular domain of the transferrin receptor 2 for diagnosis and treatment of primary and secondary sclerosing diseases
WO2019169283A1 (en) 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
MX2020008582A (en) * 2018-03-05 2020-09-21 Univ Saitama Medical Pharmaceutical composition for treating or preventing heterotopic ossification.
WO2019241350A1 (en) 2018-06-13 2019-12-19 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
US20210214456A1 (en) 2018-06-13 2021-07-15 Kymab Limited Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone
CA3108328A1 (en) * 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva
MX2021001284A (en) 2018-08-02 2021-07-15 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy.
WO2020086730A1 (en) * 2018-10-23 2020-04-30 Keros Therapeutics, Inc. Alk2 antibodies and methods of use thereof
MX2021007394A (en) * 2018-12-18 2021-07-15 Regeneron Pharma Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a.
MX2022008494A (en) * 2020-01-08 2022-10-10 Regeneron Pharma Treatment of fibrodysplasia ossificans progressiva.
WO2021142260A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of acvr1
EP4168038A1 (en) * 2020-06-18 2023-04-26 Regeneron Pharmaceuticals, Inc. Activin a antibody formulations and methods of use thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
TW202328190A (en) * 2021-09-03 2023-07-16 大陸商來凱醫藥科技（上海）有限公司 Anti-acvr2a antibodies and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (en) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド Method for producing xenogeneic immunoglobulin and transgenic mouse
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69230142T2 (en) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. METHOD FOR PRODUCING SPECIFIC BINDING PAIRS
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH07503132A (en) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド Transgenic non-human animals capable of producing xenoantibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
KR100483832B1 (en) 1999-02-05 2005-04-20 삼성전자주식회사 Method of describing image texture descriptor
CN1671416B (en) 2001-07-12 2013-01-02 杰斐逊·富特 Super-humanized antibodies
AU2005206536B2 (en) 2004-01-16 2010-09-02 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2006012627A2 (en) 2004-07-23 2006-02-02 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8859752B2 (en) * 2006-04-18 2014-10-14 The Trustees Of The University Of Pennsylvania SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
CN101627055A (en) * 2006-09-05 2010-01-13 梅达雷克斯公司 Antibodies to bone morphogenetic proteins and their receptors and methods of use thereof
CL2007002567A1 (en) * 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
TWI432449B (en) 2007-02-02 2014-04-01 Acceleron Pharma Inc Variants derived from actriib and uses therefor
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
JP5270913B2 (en) 2007-12-26 2013-08-21 サンゴバン・ティーエム株式会社 High electrical resistance high zirconia cast refractory
WO2009114180A1 (en) * 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
US8946185B2 (en) * 2010-06-18 2015-02-03 Lsip, Llc Agent for suppressing expression of dominant allele
WO2013063536A1 (en) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
PL2780368T3 (en) * 2011-11-14 2018-06-29 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
WO2014051109A1 (en) 2012-09-28 2014-04-03 協和発酵キリン株式会社 Anti-human bmp9 antibody and treatment agent for ectopic ossification disease containing said antibody as active ingredient
TWI635098B (en) 2013-02-01 2018-09-11 再生元醫藥公司 Antibodies comprising chimeric constant domains
TW201920262A (en) * 2013-07-30 2019-06-01 美商再生元醫藥公司 Anti-activin A antibodies and uses thereof
JP6601687B2 (en) * 2014-03-31 2019-11-06 大日本住友製薬株式会社 Preventive and therapeutic agent for progressive ossification fibrodysplasia
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
WO2016130986A1 (en) * 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
US20160319009A1 (en) 2015-04-29 2016-11-03 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva

Also Published As

Publication number Publication date
SG10201902175RA (en) 2019-04-29
EP3604335A1 (en) 2020-02-05
IL251063B (en) 2022-08-01
RS59412B1 (en) 2019-11-29
WO2016039796A2 (en) 2016-03-17
KR102564079B1 (en) 2023-08-08
PL3191512T3 (en) 2020-01-31
CN107106648B (en) 2021-06-11
JP2017528476A (en) 2017-09-28
AU2015315829B2 (en) 2021-05-27
BR112017004812A2 (en) 2017-12-12
US11407822B2 (en) 2022-08-09
CY1122188T1 (en) 2020-11-25
JP6560341B2 (en) 2019-08-14
MX2017003175A (en) 2017-06-06
MY179654A (en) 2020-11-11
EP3191512A2 (en) 2017-07-19
ZA201702112B (en) 2018-05-30
ES2739605T3 (en) 2020-02-03
US20160075772A1 (en) 2016-03-17
LT3191512T (en) 2019-09-10
DK3191512T3 (en) 2019-08-12
SG11201701913SA (en) 2017-04-27
MA40621B1 (en) 2019-11-29
TW201625302A (en) 2016-07-16
NZ730773A (en) 2022-07-01
AU2015315829A1 (en) 2017-04-27
EP3191512B1 (en) 2019-07-24
SI3191512T1 (en) 2019-09-30
PT3191512T (en) 2019-09-26
WO2016039796A3 (en) 2016-06-16
TWI688402B (en) 2020-03-21
HUE046558T2 (en) 2020-03-30
KR20170052666A (en) 2017-05-12
IL251063A0 (en) 2017-04-30
US20180111983A1 (en) 2018-04-26
MA40621A (en) 2017-07-19
US20200115440A1 (en) 2020-04-16
CA2960950C (en) 2023-03-14
CL2017000603A1 (en) 2017-10-06
ME03541B (en) 2020-07-20
CN107106648A (en) 2017-08-29
CA2960950A1 (en) 2016-03-17
HRP20191929T1 (en) 2020-01-10

Similar Documents

Publication Publication Date Title
CL2018002962A1 (en) Treatment of progressive ossifying fibrodysplasia (divisional of application No. 603-2017.
PH12019501448A1 (en) Immunomodulator compounds and methods of use
PH12017501521A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
CO2017000507A2 (en) Chimeric bcma antigen receptor
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
SV2016005311A (en) COMPOUNDS AND COMPOSITIONS AS AGENTS OF THE TOLL TYPE 7 RECEIVER
CO2017000510A2 (en) Car constructs
EA201791093A1 (en) ANTIBODIES TO CD47, METHODS AND USE
CO2017001573A2 (en) Chimeric anti-cd123 antigen receptor
NZ737399A (en) Ccr2 modulators
MY193661A (en) Anti-tim3 antibodies and methods of use
PH12017500825A1 (en) Anti-cldn chimeric antigen receptors and methods of use
CL2018001722A1 (en) New anti-mfi2 antibodies and methods of use (divisional application 201700506)
UY36021A (en) FC MULTIMÈRIC PROTEINS
EA201692529A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS USING FOLLYSTATINE POLYPEPTIDES
MY176855A (en) Anti-jagged1 antibodies and methods of use
SG10201907501QA (en) Antibodies and assays for detection of folate receptor 1
EA201692395A1 (en) NEW CONNECTIONS
MX2023006786A (en) Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors.
EA201791450A1 (en) 3,5-DIAMINOPYRAZOLES KINASE INHIBITORS
MX2019014090A (en) Methods for the treatment of chronic pouchitis.
AR101856A1 (en) TREATMENT OF PROGRESSIVE OSIFYING FIBRODISPLASIA
MX2019002349A (en) Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors.
UA98640U (en) Method of treating the generalized anxiety disorder with prevalence of a somatovegetative component of anxiety of elderly people